Xu Yumei, Hong Tao, Li Wanming
Department of Ophthalmology, Beijing Aerospace General Hospital, Beijing 100076, China. Email:
Zhonghua Yi Xue Za Zhi. 2015 Feb 10;95(6):440-3.
To explore the efficacies and complications of Ahmed glaucoma valve implantation for treating refractory glaucoma.
A retrospective study of case series was conducted for 24 patients (26 eyes) with refractory glaucoma from February 2001 to July 2008 at our hospital. Ahmed glaucoma valve implantation was performed. Pre- and post-operative best spectacle-corrected visual acuity (BSCVA), intraocular pressure (IOP), number of medications and complications were recorded and analyzed. The follow-up period was 58-159 months.
The post-operative values of IOP were 13.02+/-6.79, 11.43+/-5.24 and 18.56+/-6.43 mmHg at 1 day, 1 month and the last follow-up respectively. There were significant difference when compared with pre-operative IOP (37.59+/-10.76 mmHg, P < 0.01). And 65.38% of eyes maintained or gained ≥ 1 line of BSCVA. But there was no significant difference with pre-operative BSCVA (P = 0.110). Twenty eyes required anti-glaucoma drugs after glaucoma valve implantation and the average number of medication was 1.72+/-0.98. There was significant difference with the pre-operative medication number 2.7 ± 0.7 (P = 0.001). The surgical success rate was 73.1%. And the causes of failure were endophthalmitis, corneal endothelial decompensation, persistent conjunctival wound non-healing, glaucoma valve exposure and loss of light perception.Early postoperative complications were ocular hypotony, shallow anterior chamber, hyphema, transient high IOP and tube occlusion. And long-term complications included encapsulated cyst formation, tube exposure, corneal endothelial decompensation and endophthalmitis.
Ahmed glaucoma valve implantation is efficacious for refractory glaucoma.However, clinicians should pay attention to the prevention and treatment of complications.
探讨Ahmed青光眼引流阀植入术治疗难治性青光眼的疗效及并发症。
对我院2001年2月至2008年7月收治的24例(26只眼)难治性青光眼患者进行回顾性病例系列研究。行Ahmed青光眼引流阀植入术。记录并分析术前及术后最佳矫正视力(BSCVA)、眼压(IOP)、用药数量及并发症情况。随访时间为58 - 159个月。
术后1天、1个月及末次随访时的眼压值分别为13.02±6.79、11.43±5.24和18.56±6.43 mmHg。与术前眼压(37.59±10.76 mmHg)相比,差异有统计学意义(P < 0.01)。65.38%的患眼BSCVA维持或提高了≥1行。但与术前BSCVA相比,差异无统计学意义(P = 0.110)。20只眼在植入青光眼引流阀后需要使用抗青光眼药物,平均用药数量为1.72±0.98。与术前用药数量2.7±0.7相比,差异有统计学意义(P = 0.001)。手术成功率为73.1%。失败原因包括眼内炎、角膜内皮失代偿、结膜伤口持续不愈合、青光眼引流阀暴露及无光感。术后早期并发症有低眼压、前房浅、前房积血、短暂性高眼压及引流管阻塞。长期并发症包括包裹性囊肿形成、引流管暴露、角膜内皮失代偿及眼内炎。
Ahmed青光眼引流阀植入术治疗难治性青光眼有效。然而,临床医生应注意并发症的防治。